Cases
Dr. Reddy's Laboratories Ltd. (NYSE: RDY)
Securities Class Action
Overview
Overview
- Date:
- 11/10/2015
- Company Name:
- Dr. Reddy's Laboratories Limited
- Status:
- Closed/Complete
NEW YORK, November 10, 2015 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) investors concerning whether the company’s officers and board of directors violated the federal securities laws.
On November 6, 2015, Dr. Reddy’s disclosed that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India. Dr. Reddy’s said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the problems. The manufacturing plants account for more than 10% of Dr. Reddy’s sales.
Following this news, shares of Dr. Reddy’s fell $11.75 per share, or over 18%, to close at $53.50 per share on November 6, 2015.
If you purchased Dr. Reddy’s securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On November 6, 2015, Dr. Reddy’s disclosed that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India. Dr. Reddy’s said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the problems. The manufacturing plants account for more than 10% of Dr. Reddy’s sales.
Following this news, shares of Dr. Reddy’s fell $11.75 per share, or over 18%, to close at $53.50 per share on November 6, 2015.
If you purchased Dr. Reddy’s securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.